{
    "clinical_study": {
        "@rank": "132634", 
        "arm_group": [
            {
                "arm_group_label": "Aleglitazar", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to\n      assess the effect of aleglitazar on cardiac energetics and function in patients with\n      uncomplicated type 2 diabetes mellitus and no history of coronary artery disease who are\n      drug-na\u00efve or treated with stable metformin. Eligible patients will receive either 150 mcg\n      aleglitazar or placebo orally daily for 6 weeks. After a washout period of 6 weeks, patients\n      will cross over to the treatment not yet received."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 40 to 70 years of age (inclusive) at screening\n\n          -  Patients with Type 2 diabetes mellitus diagnosed at least 12 weeks before screening\n             and either drug-na\u00efve or treated with stable metformin monotherapy for at least 12\n             weeks prior to screening\n\n          -  HbA1c >/= 7 % and </= 9% at screening\n\n          -  Absence of history of coronary artery disease\n\n        Exclusion Criteria:\n\n          -  Diagnosis or history of Type 1 diabetes mellitus, diabetes resulting from pancreatic\n             injury, or secondary forms of diabetes\n\n          -  Current treatment with fibrates, thiazolidinediones, or insulin\n\n          -  Prior intolerance to thiazolidinediones and/or fibrates\n\n          -  Clinically significant liver disease or impaired liver function\n\n          -  Know chronic diabetic complications (i.e. retinopathy, neuropathy, nephropathy)\n\n          -  Symptomatic congestive heart failure classified as NYHA class II-IV\n\n          -  Diagnosed and/or treated malignancy within the past 5 years, except for treated basal\n             cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer\n\n          -  Contraindications to MRI, or inability to tolerate MRI scanning"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680978", 
            "org_study_id": "BC25445"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aleglitazar", 
                "description": "150 mcg orally daily, 6 weeks", 
                "intervention_name": "aleglitazar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "orally daily, 6 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oxford", 
                    "country": "United Kingdom", 
                    "zip": "OX3 9DU"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A SINGLE CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, PHASE II STUDY TO ASSESS THE EFFECT OF ALEGLITAZAR ON CARDIAC ENERGETICS AND FUNCTION IN PATIENTS WITH UNCOMPLICATED TYPE 2 DIABETES MELLITUS AND NO HISTORY OF CORONARY ARTERY DISEASE WHO ARE DRUG-NA\u00cfVE OR TREATED WITH STABLE METFORMIN MONOTHERAPY", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS)", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in left ventricular diastolic function measured by mitral inflow, tissue Doppler Imaging and magnetic resonance imaging (MRI)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 6"
            }, 
            {
                "measure": "Change in cardiac/hepatic triglyceride content assessed my MRS", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 6"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}